Literature DB >> 29730448

A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans.

Matthew Clark1, Thomas Steger-Hartmann2.   

Abstract

Although lack of efficacy is an important cause of late stage attrition in drug development the shortcomings in the translation of toxicities observed during the preclinical development to observations in clinical trials or post-approval is an ongoing topic of research. The concordance between preclinical and clinical safety observations has been analyzed only on relatively small data sets, mostly over short time periods of drug approvals. We therefore explored the feasibility of a big-data analysis on a set of 3,290 approved drugs and formulations for which 1,637,449 adverse events were reported for both humans animal species in regulatory submissions over a period of more than 70 years. The events reported in five species - rat, dog, mouse, rabbit, and cynomolgus monkey - were treated as diagnostic tests for human events and the diagnostic power was computed for each event/species pair using likelihood ratios. The animal-human translation of many key observations is confirmed as being predictive, such as QT prolongation and arrhythmias in dog. Our study confirmed the general predictivity of animal safety observations for humans, but also identified issues of such automated analyses which are on the one hand related to data curation and controlled vocabularies, on the other hand to methodological changes over the course of time.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse event; Big data; Concordance; Predictive value; Predictivity of animal studies; Risk assessment; Signal detection; Translation

Mesh:

Substances:

Year:  2018        PMID: 29730448     DOI: 10.1016/j.yrtph.2018.04.018

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  19 in total

Review 1.  Human-Derived Organ-on-a-Chip for Personalized Drug Development.

Authors:  Yasamin A Jodat; Min G Kang; Kiavash Kiaee; Gyeong J Kim; Angel F H Martinez; Aliza Rosenkranz; Hojae Bae; Su R Shin
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

2.  A Unidirectional 96-Well Fluidic Culture Platform for Upstream Cell Dosing with Subsequent Downstream Nonlinear and Ascending Exposure Gradients for Real-Time and Cell-Based Toxicity Screening Environments.

Authors:  Bincy A John; David J Sloan; Timothy C Jensen; Sreenivasa C Ramaiahgari; Peter End; Gabrielle E Resh; Randall E McClelland
Journal:  Appl In Vitro Toxicol       Date:  2021-12-16

3.  Mechanism-driven modeling of chemical hepatotoxicity using structural alerts and an in vitro screening assay.

Authors:  Xuelian Jia; Xia Wen; Daniel P Russo; Lauren M Aleksunes; Hao Zhu
Journal:  J Hazard Mater       Date:  2022-05-20       Impact factor: 14.224

Review 4.  Monitoring haemodynamic changes in rodent models to better inform safety pharmacology: Novel insights from in vivo studies and waveform analysis.

Authors:  Marieke Van Daele; Samantha L Cooper; Patrizia Pannucci; Edward S Wragg; Julie March; Iwan de Jong; Jeanette Woolard
Journal:  JRSM Cardiovasc Dis       Date:  2022-05-23

5.  In vitro toxicological assessment of free 3-MCPD and select 3-MCPD esters on human proximal tubule HK-2 cells.

Authors:  Miriam E Mossoba; Mapa S T Mapa; Magali Araujo; Yang Zhao; Brenna Flannery; Thomas Flynn; Jessica Sprando; Paddy Wiesenfeld; Robert L Sprando
Journal:  Cell Biol Toxicol       Date:  2019-11-05       Impact factor: 6.691

6.  Improving natural product research translation: From source to clinical trial.

Authors:  Barbara C Sorkin; Adam J Kuszak; Gregory Bloss; Naomi K Fukagawa; Freddie Ann Hoffman; Mahtab Jafari; Bruce Barrett; Paula N Brown; Frederic D Bushman; Steven J Casper; Floyd H Chilton; Christopher S Coffey; Mario G Ferruzzi; D Craig Hopp; Mairead Kiely; Daniel Lakens; John B MacMillan; David O Meltzer; Marco Pahor; Jeffrey Paul; Kathleen Pritchett-Corning; Sara K Quinney; Barbara Rehermann; Kenneth D R Setchell; Nisha S Sipes; Jacqueline M Stephens; D Lansing Taylor; Hervé Tiriac; Michael A Walters; Dan Xi; Giovanna Zappalá; Guido F Pauli
Journal:  FASEB J       Date:  2019-12-10       Impact factor: 5.834

7.  Long-Term Expansion of Functional Human Pluripotent Stem Cell-Derived Hepatic Organoids.

Authors:  Seon Ju Mun; Yeon-Hwa Hong; Hyo-Suk Ahn; Jae-Sung Ryu; Kyung-Sook Chung; Myung Jin Son
Journal:  Int J Stem Cells       Date:  2020-07-30       Impact factor: 2.500

8.  Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines.

Authors:  Francois Busquet; Thomas Hartung; Giorgia Pallocca; Costanza Rovida; Marcel Leist
Journal:  Arch Toxicol       Date:  2020-05-23       Impact factor: 5.153

Review 9.  Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development.

Authors:  Xiying Lin; Jiayu Tang; Yan-Ru Lou
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-30

10.  Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity.

Authors:  Jessica M Miller; Moustafa H Meki; Qinghui Ou; Sharon A George; Anna Gams; Riham R E Abouleisa; Xian-Liang Tang; Brooke M Ahern; Guruprasad A Giridharan; Ayman El-Baz; Bradford G Hill; Jonathan Satin; Daniel J Conklin; Javid Moslehi; Roberto Bolli; Alexandre J S Ribeiro; Igor R Efimov; Tamer M A Mohamed
Journal:  Toxicol Appl Pharmacol       Date:  2020-08-30       Impact factor: 4.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.